Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Diabetics with high blood pressure benefit from ’water pills’

28.06.2005


Diuretics (water pills) work better than newer and more costly medicines in the treatment of high blood pressure and prevention of some forms of heart disease in people with type 2 diabetes, according to results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT, the largest hypertension clinical trial ever conducted, was led in part by Tulane University physician and epidemiologist Paul K. Whelton, senior vice president for health sciences and lead author for the current report published in the June 27th issue of the Archives of Internal Medicine.

"Almost three out of every four persons with type 2 diabetes has hypertension, putting them at substantial risk for cardiovascular disease," Whelton says.

An important question in patients with type 2 diabetes and hypertension has been whether it makes a difference which medicine is used for initial therapy of high blood pressure.



"ALLHAT is the largest study to address this question, comparing four different classes of antihypertensive medication: diuretics, angiotensin-converting enzyme [ACE] inhibitors, calcium channel blockers and alpha receptor blockers," Whelton says.

In an earlier publication (Journal of the American Medical Association, December 2002), the ALLHAT investigators reported that diuretics were superior in preventing adverse cardiovascular disease outcomes compared with other first-step antihypertensive medications. The current report indicates that this is true not only in hypertensive patients with a normal blood sugar, but in those with diabetes, or an impaired fasting glucose (pre-diabetes).

The Archives publication was based on long-term clinical trial experience in 31,512 men and women who were all 55 years old or older with stage 1 or stage 2 hypertension and at least one additional risk factor for coronary heart disease. Study participants were assigned to initial treatment with either a calcium channel blocker (amlodipine), an ACE inhibitor (lisinopril) or a diuretic (chlorthalidone). Compared with the ACE inhibitor and the calcium channel blocker, the diuretic was:

  • More protective against heart failure in patients with or without diabetes (by about 1/6th compared with the ACE inhibitor, and by about 1/3rd compared with the calcium channel blocker).
  • More protective against stroke in people with or without diabetes (compared with the ACE inhibitor). This benefit was seen only in Black patients.
  • Slightly more effective in lowering systolic blood pressure-the measure of blood pressure when the heart beats-among those with or without diabetes.
  • At least equally protective against fatal coronary heart disease or non-fatal heart attacks in diabetics, those with an impaired fasting glucose, and in those with a normal blood sugar.
  • Equally protective against death, end-stage renal disease or cancer in diabetics, those with an impaired fasting glucose, and in those with a normal blood sugar.

"Independent of diabetes status, our results suggest that diuretics are better than ACE inhibitors and calcium channel blockers in preventing certain cardiovascular disease complications-especially heart failure-during initial treatment of high blood pressure. Patients with diabetes and high blood pressure should not change their antihypertensive medications without discussing this option with their doctors," says Whelton.

Madeline Vann | EurekAlert!
Further information:
http://www.tulane.edu

More articles from Health and Medicine:

nachricht Correct connections are crucial
26.06.2017 | Charité - Universitätsmedizin Berlin

nachricht One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Dune ecosystem modelling

26.06.2017 | Ecology, The Environment and Conservation

Insights into closed enzymes

26.06.2017 | Life Sciences

Quantum thermometer or optical refrigerator?

23.06.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>